ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 479,40
-0,68%
Dow Jones
39 118,86
-0,12%
DAX
18 235,45
0,17%
Brent Oil
84,85
0,00%
Bitcoin
61 602,39
1,17%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Kiromic BioPharma Inc (KRBP)

  7. Kiromic BioPharma Inc (KRBP) Actualités

KRBP

Kiromic BioPharma (KRBP)

Kiromic BioPharma Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:KRBP
DateHeureSourceTitreSymboleSociété
28/06/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRBPKiromic BioPharma Inc
20/06/202414h00Business WireKiromic BioPharma Provides Updates on its Deltacel-01 Clinical TrialNASDAQ:KRBPKiromic BioPharma Inc
14/06/202400h32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRBPKiromic BioPharma Inc
06/06/202414h00Business WireKiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical TrialNASDAQ:KRBPKiromic BioPharma Inc
29/05/202414h00Business WireKiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical TrialNASDAQ:KRBPKiromic BioPharma Inc
22/05/202423h03Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KRBPKiromic BioPharma Inc
20/05/202423h00Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:KRBPKiromic BioPharma Inc
20/05/202414h00Business WireKiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial SiteNASDAQ:KRBPKiromic BioPharma Inc
20/05/202412h29Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:KRBPKiromic BioPharma Inc
17/05/202422h43Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:KRBPKiromic BioPharma Inc
24/04/202414h08Business WireKiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three PatientsNASDAQ:KRBPKiromic BioPharma Inc
10/04/202422h30Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:KRBPKiromic BioPharma Inc
02/04/202414h18Business WireKiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical TrialNASDAQ:KRBPKiromic BioPharma Inc
21/03/202422h21Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:KRBPKiromic BioPharma Inc
19/03/202413h08Business WireEarly Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical TrialNASDAQ:KRBPKiromic BioPharma Inc
01/03/202414h08Business WireKiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 TrialNASDAQ:KRBPKiromic BioPharma Inc
29/02/202400h30Business WireKiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7thNASDAQ:KRBPKiromic BioPharma Inc
14/02/202414h08Business WireResults from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two MonthsNASDAQ:KRBPKiromic BioPharma Inc
29/01/202413h47Business WireKiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung CancerNASDAQ:KRBPKiromic BioPharma Inc
05/01/202414h08Business WireKiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical TrialNASDAQ:KRBPKiromic BioPharma Inc
14/12/202314h17Business Wire Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung CancerNASDAQ:KRBPKiromic BioPharma Inc
13/09/202322h35Business WireKiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14NASDAQ:KRBPKiromic BioPharma Inc
15/08/202322h16Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:KRBPKiromic BioPharma Inc
14/08/202322h52Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KRBPKiromic BioPharma Inc
24/07/202321h00Business WireKiromic BioPharma Welcomes Two New Directors to its BoardNASDAQ:KRBPKiromic BioPharma Inc
18/07/202322h22Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KRBPKiromic BioPharma Inc
29/06/202322h34Edgar (US Regulatory)Securities Registration Statement (s-1)NASDAQ:KRBPKiromic BioPharma Inc
29/06/202322h33Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:KRBPKiromic BioPharma Inc
27/06/202322h16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:KRBPKiromic BioPharma Inc
19/05/202322h50Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:KRBPKiromic BioPharma Inc
 Showing the most relevant articles for your search:NASDAQ:KRBP

Dernières Valeurs Consultées

USOTC
TGONF
Tetragon Financial (CE)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés